Compare Procter & Gamble Health with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PROCTER & GAMBLE HEALTH vs NATCO PHARMA - Comparison Results

PROCTER & GAMBLE HEALTH     Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PROCTER & GAMBLE HEALTH NATCO PHARMA PROCTER & GAMBLE HEALTH/
NATCO PHARMA
 
P/E (TTM) x 18.0 31.6 56.9% View Chart
P/BV x 7.2 4.5 161.1% View Chart
Dividend Yield % 6.5 0.8 872.3%  

Financials

 PROCTER & GAMBLE HEALTH   NATCO PHARMA
EQUITY SHARE DATA
    PROCTER & GAMBLE HEALTH
Dec-18
NATCO PHARMA
Mar-19
PROCTER & GAMBLE HEALTH/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs3,549849 418.0%   
Low Rs1,301557 233.6%   
Sales per share (Unadj.) Rs511.4573.8 89.1%  
Earnings per share (Unadj.) Rs61.3176.0 34.8%  
Cash flow per share (Unadj.) Rs74.0198.2 37.3%  
Dividends per share (Unadj.) Rs440.006.25 7,040.0%  
Dividend yield (eoy) %18.10.9 2,040.7%  
Book value per share (Unadj.) Rs927.8842.7 110.1%  
Shares outstanding (eoy) m16.6036.50 45.5%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x4.71.2 387.1%   
Avg P/E ratio x39.64.0 990.6%  
P/CF ratio (eoy) x32.83.5 923.8%  
Price / Book Value ratio x2.60.8 313.4%  
Dividend payout %717.93.6 20,216.3%   
Avg Mkt Cap Rs m40,25725,660 156.9%   
No. of employees `0001.15.0 22.9%   
Total wages/salary Rs m1,3133,559 36.9%   
Avg. sales/employee Rs Th7,486.74,225.3 177.2%   
Avg. wages/employee Rs Th1,157.6718.0 161.2%   
Avg. net profit/employee Rs Th897.21,295.9 69.2%   
INCOME DATA
Net Sales Rs m8,49020,945 40.5%  
Other income Rs m2441,302 18.7%   
Total revenues Rs m8,73422,247 39.3%   
Gross profit Rs m1,4827,948 18.6%  
Depreciation Rs m211810 26.1%   
Interest Rs m0193 0.0%   
Profit before tax Rs m1,5148,247 18.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m660-   
Tax Rs m5631,823 30.9%   
Profit after tax Rs m1,0176,424 15.8%  
Gross profit margin %17.537.9 46.0%  
Effective tax rate %37.122.1 168.0%   
Net profit margin %12.030.7 39.1%  
BALANCE SHEET DATA
Current assets Rs m15,34323,472 65.4%   
Current liabilities Rs m1,9607,287 26.9%   
Net working cap to sales %157.677.3 204.0%  
Current ratio x7.83.2 243.0%  
Inventory Days Days4992 52.9%  
Debtors Days Days2888 32.2%  
Net fixed assets Rs m1,20918,648 6.5%   
Share capital Rs m166365 45.5%   
"Free" reserves Rs m15,23534,525 44.1%   
Net worth Rs m15,40130,760 50.1%   
Long term debt Rs m00-   
Total assets Rs m17,59543,031 40.9%  
Interest coverage xNM43.7-  
Debt to equity ratio x00-  
Sales to assets ratio x0.50.5 99.1%   
Return on assets %5.815.4 37.6%  
Return on equity %6.620.9 31.6%  
Return on capital %10.327.4 37.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m1,63611,536 14.2%   
Fx outflow Rs m4,3682,939 148.6%   
Net fx Rs m-2,7328,597 -31.8%   
CASH FLOW
From Operations Rs m-1,3046,688 -19.5%  
From Investments Rs m12,697-6,122 -207.4%  
From Financial Activity Rs m-301-509 59.0%  
Net Cashflow Rs m11,09366 16,807.4%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 51.8 1.5 3,523.8%  
Indian inst/Mut Fund % 18.2 7.8 232.1%  
FIIs % 1.0 16.6 6.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 26.0 111.9%  
Shareholders   28,591 25,395 112.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PROCTER & GAMBLE HEALTH With:   JUBILANT PHARMOVA   PANACEA BIOTECH  GLENMARK PHARMA  GSK PHARMA  FRESENIUS KABI ONCO.  

Compare PROCTER & GAMBLE HEALTH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

A Time Correction in the Nifty(Momentum Moves)

The week belonged to the bulls after bears ended the party in February. March started with gains for the bulls but historically, March has been a bears' month.

Related Views on News

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY21); Net Profit Up 57.0% (Quarterly Result Update)

Aug 31, 2020 | Updated on Aug 31, 2020

For the quarter ended June 2020, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 692 m (up 57.0% YoY). Sales on the other hand came in at Rs 6 bn (up 171.6% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (2QFY20); Net Profit Down 13.0% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 358 m (down 13.0% YoY). Sales on the other hand came in at Rs 2 bn (down 0.4% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

Gold 65,000 and Silver 84,000 in 2022

Feb 26, 2021

In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

PROCTER & GAMBLE HEALTH SHARE PRICE


Mar 5, 2021 (Close)

TRACK PROCTER & GAMBLE HEALTH

  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PROCTER & GAMBLE HEALTH

PROCTER & GAMBLE HEALTH - DIVIS LABORATORIES COMPARISON

COMPARE PROCTER & GAMBLE HEALTH WITH

MARKET STATS